A 32-year-old man from rural India presents with a 10-month history of progressive swelling over the right distal radius. He reports mild pain and occasional clicking sensation. On examination, there is a firm, non-mobile mass over the dorsal aspect of the distal radius. X-ray reveals a lytic lesion with well-defined borders and a soap-bubble pattern in the epiphyseal-metaphyseal region. The lesion is 4 cm in size. What is the most appropriate next step in management?

Explanation

## Management of Giant Cell Tumor: Surgical Strategy ### Treatment Algorithm ```mermaid flowchart TD A[GCT Diagnosis Confirmed]:::outcome --> B{Resectable & Accessible?}:::decision B -->|Yes| C{Aggressive Features?}:::decision B -->|No| D[Denosumab + Consider Curettage]:::action C -->|No| E[Curettage + Adjuvant Therapy]:::action C -->|Yes| F[Wide Excision]:::action E --> G[Phenol/Liquid Nitrogen/High-Speed Burr]:::action G --> H[Bone Graft or Cement Packing]:::action F --> I[Reconstruction if needed]:::action H --> J[Follow-up: 6-12 months]:::outcome I --> J ``` ### First-Line Treatment: Curettage with Adjuvant Therapy **High-Yield:** Intralesional curettage (not wide excision) is the standard of care for accessible, non-aggressive GCT. The goal is to preserve bone stock and joint function. ### Adjuvant Modalities to Reduce Recurrence | Modality | Mechanism | Recurrence Rate | Notes | |----------|-----------|-----------------|-------| | **Phenol** | Chemical cauterization | 10–15% | Most commonly used; cost-effective | | **Liquid nitrogen** | Cryotherapy | 8–12% | Effective but risk of pathological fracture | | **High-speed burr** | Mechanical ablation | 12–18% | Safest for articular surfaces | | **Cement packing** | Mechanical fill + heat | 15–20% | Easier revision if recurrence | **Key Point:** Phenol application is the most commonly used adjuvant in India due to cost-effectiveness and proven efficacy in reducing recurrence from ~50% (curettage alone) to ~10–15%. ### Why NOT Wide Excision Here? **Clinical Pearl:** Wide excision (3 cm margin) is reserved for: - Aggressive, rapidly growing lesions - Recurrent GCT (failed curettage) - Lesions with cortical breakthrough and soft tissue extension - Lesions threatening vital structures This patient has a well-demarcated, accessible lesion in the distal radius — wide excision would unnecessarily sacrifice bone and impair wrist function. ### Why NOT Observation? **Warning:** GCT is locally aggressive and will continue to expand, causing: - Progressive bone destruction - Pathological fracture risk - Joint involvement and arthritis - Functional impairment Observation is NOT appropriate for a symptomatic, growing lesion. ### Role of Denosumab **Key Point:** Denosumab (RANKL inhibitor) is used for: - Unresectable GCT - Metastatic GCT (rare) - Neoadjuvant therapy to reduce vascularity and tumor size before curettage in highly aggressive cases For a standard, accessible GCT, preoperative denosumab is not indicated and delays definitive treatment. ### Expected Outcome Curettage + phenol + bone graft has: - Recurrence rate: 10–15% - Preservation of limb function - Low morbidity - Cost-effective